263
â–¡ CASE REPORT â–¡
Granuloma-forming Interstitial Pneumonia Occurring
One Year after the Start of Everolimus Therapy
Yoshinobu Saito 1
, Shinobu Kunugi 2
, Yasutomo Suzuki 3
, Kousuke Narita 1
, Yukiko Miura 1
,
Yuji Minegishi 1
, Go Kimura 3
, Yukihiro Kondo 3
, Arata Azuma 1
,
Yuh Fukuda 2 and Akihiko Gemma 1
Abstract
We experienced a case of interstitial lung disease (ILD) that occurred one year after the start of everolimus
therapy for renal cell carcinoma. The pathological features included interstitial pneumonia with granuloma
formation. Everolimus is known to cause ILD; however, its pathology is unclear. Granuloma-forming interstiï¿¾tial pneumonia associated with everolimus is uncommon, although it may be one of the pathological patterns
associated with everolimus-induced ILD. This is a slow-onset case of everolimus-induced ILD in a patient
with renal cell carcinoma. Physicians should thus be aware of the potential for the development of ILD at
any time during the administration of everolimus therapy.
Key words: everolimus, renal cell carcinoma, drug-induced, interstitial pneumonia, granuloma, KL-6
(Intern Med 52: 263-267, 2013)
(DOI: 10.2169/internalmedicine.52.8588)
Introduction
Everolimus, an inhibitor of mammalian target of rapamyï¿¾cin (mTOR), is used as an immunosuppressant postï¿¾transplantation or as an anti-cancer drug for renal cell carciï¿¾noma (RCC) and pancreatic neuroendocrine tumors. Interstiï¿¾tial lung disease (ILD) is one of the major adverse drug reï¿¾actions associated with everolimus therapy, with a frequency
that seems to be much higher than that occurring during
treatment with other anti-cancer drugs (1). The epidemiolï¿¾ogy of everolimus-induced ILD is becoming evident based
on an all-case post-marketing surveillance study conducted
in Japan. The interim analysis of this study showed that ILD
was diagnosed in 105 of 605 treated cases (17.4%) (2).
Many patients have developed ILD; however, only a small
number of patients have undergone bronchoscopy to obtain
a definitive diagnosis of ILD (bronchoalveolar lavage was
performed in eight of 105 cases) (2). As a result, the pathoï¿¾logical findings of everolimus-induced ILD have not yet
been fully elucidated.
We herein present a case of ILD that occurred one year
after the start of everolimus therapy in a patient with RCC.
ILD was diagnosed based on clinical, radiographic and
pathological findings. A transbronchial lung biopsy showed
interstitial pneumonia with distinct granuloma formation. In
this report, we also review previous reports describing
pathological findings of the lungs in patients with
everolimus-induced ILD.
Case Report
The patient was a 62-year-old man who had been diagï¿¾nosed with clear cell RCC five years earlier. He had a hisï¿¾tory of pulmonary tuberculosis occurring six years before
his presentation with ILD. He had been cured with antituï¿¾berculous drugs. The RCC had been treated with surgery,
and the patient had subsequently been treated with
interferon-alpha for pulmonary metastasis. Ten months later,
the pulmonary metastasis relapsed. Sorafenib, then sunitinib,
ï¼‘Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan, ï¼’Department of Analytic Huï¿¾man Pathology, Graduate School of Medicine, Nippon Medical School, Japan and ï¼“Department of Urology, Graduate School of Medicine, Nipï¿¾pon Medical School, Japan
Received for publication July 12, 2012; Accepted for publication October 16, 2012
Correspondence to Dr. Yoshinobu Saito, yo-saito@nms.ac.jp

Intern Med 52: 263-267, 2013 DOI: 10.2169/internalmedicine.52.8588
264
Figure 1. A. A chest X-ray performed at the onset of ILD showed bilateral infiltrative shadows in 
the middle and lower lung zones. B. A chest CT scan performed at the onset of ILD showed patchy
or diffuse ground grass opacities primarily in the lower lobes of both lungs. Pulmonary metastatic 
legions were also seen (arrows).
Figure 2. A. Numerous intra-alveolar granulomas (arrowï¿¾heads), focal intra-alveolar fibrotic lesions (*) and hyperplasï¿¾tic type II alveolar epithelial cells were seen (Hematoxylin and
Eosin staining, Ã—10). B. Bud type intra-alveolar fibrosis (*) 
was present (Elastica-Masson, Ã—40). C. Aggregation of CD68
(PGM-1)-positive macrophages was noted (Ã—60).
Table 1. Laboratory Data at the Diagnosis of ILD
Complete Blood Cell Counts Blood Chemistry
WBC 3,200 /È/ AST ,8/
Neutrophils 64.8% A/T ,8/
/ymphocytes 22.6% /'+ ,8/
Monocytes 7.5% È–GTP ,8/
Eosinophils 3.5% T-Bil 0.1 mJG/
Basophils 1.6% BUN 34.4 mJG/
RBC 316 Ã— 104 /È/ Cre 1.67 mJG/
+b JG/ Na 143 m(T/
+FW 26.6% K 5.2 m(T/
P/T 26.8 Ã— 104 /È/ Cl 116 m(T/
CRP 0.81 mJG/
Arterial Blood Gases (Room Air) T.P. JG/
S+ 7.304 Alb JG/
PaO2 85.6 torr
PaCO2 32.9 torr Serological Studies
+CO3
- 16.0 m(T/ K/-6 1,095.1 U/P/
BE - 9.5 m(T/ SP-' QJP/
SaO2 95.5 % È•-d-glucan < 5.0 pg/m/
was administered; however, both agents were intolerable due
to side effects of severe anorexia. Therefore, everolimus was
administered as the next treatment regimen. The RCC beï¿¾came stable after treatment with everolimus. One year after
starting everolimus therapy, the patient complained of
coughing, sputum production and dyspnea. Chest radiograï¿¾phy showed bilateral infiltrative shadows in the middle and
lower lung zones, and computed tomography (CT) revealed
patchy or diffuse ground grass opacities primarily in the
lower lobes of both lungs (Fig. 1).
The laboratory findings of the patient obtained on presenï¿¾tation are shown in Table 1. Increases in the serum levels of
LDH, KL-6 and SP-D were noted. The patient had no fever,
and a sputum culture was negative. A diagnosis of ILD was
suspected, and fiberoptic bronchoscopy was performed to
obtain the diagnosis. The results of the bronchoalveolar lavï¿¾age (BAL) analysis are shown in Table 2. Marked lymphoï¿¾cytosis and moderate eosinophilia were observed. A pathoï¿¾logical examination of the lung tissue obtained by a transï¿¾bronchial lung biopsy showed intra-alveolar fibrosis with
lymphocytes and a few eosinophils that had infiltrated into
the alveolar wall. In addition, type II pneumocyte hyperplaï¿¾sia and some binuclear pneumocytes were seen. Intraluminal
non-necrotizing granulomas were prominent (Fig. 2). The
pathological diagnosis was granuloma-forming subacute inï¿¾terstitial pneumonia. The granulomas were distributed preï¿¾dominantly in the airway, and it was thought that there was
a possibility that the granulomas were caused by a respiraï¿¾tory infection such as tuberculosis or a fungal infection.
However, no acid-fast bacilli or fungi were seen in the

Intern Med 52: 263-267, 2013 DOI: 10.2169/internalmedicine.52.8588
265
Figure 3. Chest CT scans performed at the onset of ILD (A), one week after the initiation of treatï¿¾ment with corticosteroids (B) and two months after the resumption of everolimus therapy. The 
changes in the serum KL-6 and SP-D levels around the onset of ILD (D).
Table 2. Results of the BAL Cellular Analyses
Total Cell Count Differential Cell Counts CD4+
/CD8+
Macrophages Lymphocytes Neutrophils Eosinophils
6.82Ã—105
/mL 7.2% 76.5% 0.4% 15.9% 2.0
granulomas on Ziehl-Neelsen or Alcian blue-PAS staining.
In addition, no microorganisms were cultured, and PCR asï¿¾says for Pneumocystis carinii DNA, Mycobacterium tubercuï¿¾losis DNA and Mycobacterium avium-intracellular DNA
were negative in the BAL fluid analysis. Therefore, the
granulomas were thought to have developed due to a noninï¿¾fectious cause. Based on these findings, we suspected that
the granuloma-forming interstitial pneumonia may thus have
been caused by everolimus.
The ILD did not improve despite cessation of everolimus;
therefore, administration of prednisolone at a dose of 20
mg/day was initiated. Fig. 3 shows the follow-up data for
the levels of KL-6 and SP-D and the CT results obtained afï¿¾ter treatment of the ILD. The symptoms and infiltrative
shadows resolved immediately, and the dose of prednisolone
was tapered. Although the infiltrative shadows disappeared
on follow-up CT and the serum SP-D level decreased, the
serum KL-6 level did not decrease. Afterwards, growth of
the lung metastasis was observed, and everolimus was reï¿¾started in association with a maintenance dose of prednisoï¿¾lone (10 mg/day) to prevent a recurrence of the ILD. The
ILD did not relapse throughout the patientâ€™s clinical course;
however, the serum KL-6 level gradually increased without
elevation of the serum SP-D level. The expression of KL-6
on the surface of the clear cell carcinoma was identified on
immunostaining of the surgically-resected kidney specimen.
Eventually, a metastatic tumor of the liver grew rapidly,
and the patient died four months after the resumption of
everolimus therapy due to tumor progression.
Discussion
The most distinctive feature of everolimus-induced ILD is
its high frequency. ILD occurred in 13.5% of patients reï¿¾ceiving everolimus in a phase III global clinical trial for
RCC (1). In addition, a high incidence of ILD in phase II
and III clinical trials of everolimus for cancers other than
RCC, such as breast cancer, gastric cancer and pancreatic
neuroendocrine tumors, has also been reported, with rates of
2.5-42.4%, 14.8-15.1% and 6.1-17.2%, respectively (3-9).

Intern Med 52: 263-267, 2013 DOI: 10.2169/internalmedicine.52.8588
266
Table 3. Description of the Pathological Findings or Diagnoses in Previously Reported Cases of Everoliï¿¾mus-induced ILD
Pathological findings or diagnoses Authors (year published) Reference
â€œBronchiolitis obliterans organizing pneumonia (BOOP).â€ CarreÃ±o CA, et al (2007) 11
â€œCase 1. Cellular interstitial pneumonia with giant cells and a prominent cytoplasmic 
change in histiocytes and Type 2 pneumocytes.â€
â€œCase 2. Cellular interstitial pneumonia with fibroblastic foci in alveolar spaces 
(organizing pneumonia pattern).â€
ExpÃ³sito V, et al (2008) 12
â€œLymphocytic infiltrates, where CD8 cells predominated over CD4 lymphocytes.â€ Alexandru S, et al (2008) 13
â€œBronchiolitis obliterans organizing pneumoniaâ€ O'Donnell A, et al (2008) 14
â€œIntra-alveolar lymphocytic interstitial inflammation.â€ Schrader J, et al (2010) 15
â€œIntraalveolar bleeding and the presence of hemosiderin-loaded macrophages, without 
vasculitis, necrosis, or extensive inflammation, consistent with a diagnosis of diffuse 
alveolar hemorrhage.â€
Vandewiele B, et al (2010) 16
â€œCase 1. Severe acute lung injury with features suggestive of organizing diffuse alveolar 
damage and rare giant cells.â€
â€œCase 2. Acute fibrinous and organizing pneumonia with rare, poorly formed granuloma.â€
White DA, et al (2010) 1
â€œAll cases* showed interstitial lymphocytic inflammation and mild septal thickening of 
alveolar walls mainly. Most alveoli were well-preserved, but damaged alveoli with 
fibrinous exudates, and granulation tissue occupying alveolar spaces were focally 
observed.â€ (
* : There were three cases in all.)
Mizuno R, et al (2012) 17
â€œdiffuse alveolar hemorrhageâ€ Depuydt P, et al (2012) 18
Based on the data of the interim report of the all-case surï¿¾veillance for everolimus (AFINITORâ“‡) in Japan, it was conï¿¾cluded that most cases of ILD occurred within 84 days from
the start of administration (77.1%; 81 of 105 cases). In conï¿¾trast, the occurrence of ILD more than 169 days from the
start of administration was rare (3.8%; 4 of 105 cases) (2).
The interim report also indicated that the median time to ocï¿¾currence of ILD was 57 days (the minimum and maximum
values were 5 days and 295 days, respectively). The phase
III clinical trial of everolimus for RCC showed that the meï¿¾dian time to occurrence of ILD was 108 days (range: 24 to
257 days) (1).
We experienced a case of ILD that occurred one year afï¿¾ter the start of everolimus therapy. Based on previously reï¿¾ported data regarding everolimus-induced ILD in patients
with RCC, this is a marked slow-onset case. This also sugï¿¾gests that physicians should continue to pay attention to
signs of ILD in patients being treated with everolimus.
The pathological features of this case included interstitial
pneumonia with distinct formation of granulomas. It was
necessary to distinguish between possible infectious and
noninfectious causes of the granulomas because the patient
had a history of pulmonary tuberculosis and had also reï¿¾ceived long-term treatment with everolimus, which exerts
immunosuppressive effects. However, the results of various
bacteriological examinations, including cultures and PCR
analyses, were all negative. We therefore diagnosed the
granulomas as being due to a noninfectious cause. On the
other hand, sarcoidosis and hypersensitivity pneumonitis
caused by inhalation of organic antigens are major causes of
granuloma-forming interstitial pneumonia and should thereï¿¾fore be considered in the differential diagnosis. Although
granulomas are usually distributed in the interstitium of
bronchovascular bundles and interstitial fibrosis is obscure
in patients with sarcoidosis, in this case, intra-alveolar polyï¿¾poid fibrosis was prominent and the granulomas were disï¿¾tributed in the intra-alveolar spaces. In addition, BAL cell
differentiation revealed lymphocytosis and eosinophilia;
however, eosinophilia is not usually seen in either sarcoidoï¿¾sis or hypersensitivity pneumonitis (10). Therefore, it is unï¿¾likely that granuloma-forming interstitial pneumonia would
be diagnosed as either sarcoidosis or hypersensitivity pneuï¿¾monitis. Based on an exclusive diagnosis, this case was diï¿¾agnosed as drug-induced pneumonitis, and the most likely
causative drug was thought to be everolimus.
Although the incidence of everolimus-induced ILD is
high, the number of reports that have described the patholï¿¾ogy of everolimus-induced ILD is small. Among the previï¿¾ous studies of everolimus-induced ILD written in English,
we could find only nine articles that described the pathoï¿¾logical findings of ILD (1, 11-18). Table 3 presents descripï¿¾tions of the pathological findings of everolimus-induced ILD
in these nine articles, which included 13 cases. Various
pathological patterns have been reported; however, the main
features are thought to be lymphocytic interstitial inflammaï¿¾tion and organizing pneumonia. One report briefly described
a case of everolimus-induced organizing pneumonia with
rare, poorly-formed granulomas (1). The case presented here
also involved granuloma formation; however, the granuloï¿¾mas were not poorly-formed, but rather well-formed, granuï¿¾lomas.
Drug-induced granuloma formation in the lungs is relaï¿¾tively rare, although various drugs are known to cause
granulomas, including acebutolol, etanercept, fluoxetine hyï¿¾drochloride, methotrexate, nitrofurantoin, procarbazine and
sirolimus (19). Everolimus is one of the sirolimus deriva-

Intern Med 52: 263-267, 2013 DOI: 10.2169/internalmedicine.52.8588
267
tives, and hence, the pathological pattern of everolimusï¿¾induced ILD may resemble that of sirolimus-induced ILD.
The serum level of KL-6 is an established biomarker of
interstitial pneumonia, including drug-induced interstitial
pneumonia (20, 21). The present patient presented with an
elevation of the serum KL-6 level at symptom onset, which
was useful for making the diagnosis of ILD. However, the
serum KL-6 level did not decrease even though the radioï¿¾graphic findings improved after treatment with a steroid, and
there was also a discrepancy between the trends in the seï¿¾rum KL-6 and SP-D levels (Fig. 3). Several hypotheses can
be considered regarding this problem. For example, the exï¿¾pression of KL-6 in regenerated type II pneumocytes might
have been sustained due to alveolar damage caused by the
resumption of everolimus therapy or KL-6 might have been
produced by tumor cells and leaked into the bloodstream
during tumor progression. The latter speculation is based on
the observation that the serum KL-6 level increased in paralï¿¾lel with tumor growth and the fact that the expression of
KL-6 on the surface of the tumor cells was identified on imï¿¾munostaining of the surgically-resected kidney specimen.
However, there is no supportive evidence showing that the
serum KL-6 levels increase in patients with RCC. Further
study is therefore needed to verify this speculation.
In conclusion, everolimus-induced ILD can present with
various pathological patterns, including the formation of
granulomas, and can occur any time, even more than a year
after the start of everolimus therapy. Therefore, physicians
should consistently pay attention to the possibility of ILD
during the treatment of patients with everolimus.
Authorâ€™s disclosure of potential Conflicts of Interest (COI).
Gemma A: Honoraria, Novartis Pharma.
References
1. White DA, Camus P, Endo M, et al. Noninfectious pneumonitis
after everolimus therapy for advanced renal cell carcinoma. Am J
Respir Crit Care Med 182: 396-403, 2010.
2. AFINITOR tablets 5 mg: Product information for healthcare
providers; Novartis Pharma K.K. http://product.novartis.co.jp/afi/ts/
pms_kanshitsusei_20120116.pdf (in Japanese).
3. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II
study comparing two schedules of everolimus in patients with reï¿¾current/metastatic breast cancer. J Clin Oncol 27: 4536-4541,
2009.
4. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized
study of neoadjuvant everolimus plus letrozole compared with plaï¿¾cebo plus letrozole in patients with estrogen receptor-positive
breast cancer. J Clin Oncol 27: 2630-2637, 2009.
5. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenoï¿¾pausal hormone-receptor-positive advanced breast cancer. N Engl J
Med 366: 520-529, 2012.
6. Yoon DH, Ryu MH, Park YS, et al. Phase II study of everolimus
with biomarker exploration in patients with advanced gastric canï¿¾cer refractory to chemotherapy including fluoropyrimidine and
platinum. Br J Cancer 106: 1039-1044, 2012.
7. Doi T, Muro K, Boku N, et al. Multicenter phase II study of everï¿¾olimus in patients with previously treated metastatic gastric canï¿¾cer. J Clin Oncol 28: 1904-1910, 2010.
8. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus
activity in patients with metastatic pancreatic neuroendocrine tuï¿¾mors after failure of cytotoxic chemotherapy: a phase II trial. J
Clin Oncol 28: 69-76, 2010.
9. Yao JC, Shah MH, Ito T, et al. RAD001 in Advanced Neuroendoï¿¾crine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus
for advanced pancreatic neuroendocrine tumors. N Engl J Med
364: 514-523, 2011.
10. Costabel U, Guzman J. Bronchoalveolar Lavage. In: Interstitial
Lung Disease, 5th ed. Schwalz MI, King TE Jr, Eds. Peopleâ€™s
Medical Publishing House-USA, Shelton, 2010: 149-170.
11. CarreÃ±o CA, Gadea M. Case report of a kidney transplant recipiï¿¾ent converted to everolimus due to malignancy: resolution of
bronchiolitis obliterans organizing pneumonia without everolimus
discontinuation. Transplant Proc 39: 594-595, 2007.
12. ExpÃ³sito V, de Prada JA, GÃ³mez-RomÃ¡n JJ, et al. Everolimusï¿¾related pulmonary toxicity in heart transplant recipients. J Heart
Lung Transplant 27: 797-800, 2008.
13. Alexandru S, Ortiz A, Baldovi S, et al. Severe everolimusï¿¾associated pneumonitis in a renal transplant recipient. Nephrol
Dial Transplant 23: 3353-3355, 2008.
14. Oâ€™Donnell A, Faivre S, Burris HA 3rd, et al. Phase I pharmacokiï¿¾netic and pharmacodynamic study of the oral mammalian target of
rapamycin inhibitor everolimus in patients with advanced solid tuï¿¾mors. J Clin Oncol 26: 1588-1595, 2008.
15. Schrader J, Sterneck M, Klose H, et al. Everolimus-induced pneuï¿¾monitis: report of the first case in a liver transplant recipient and
review of treatment options. Transpl Int 23: 110-113, 2010.
16. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, et al. Diffuse
alveolar hemorrhage induced by everolimus. Chest 137: 456-459,
2010.
17. Mizuno R, Asano K, Mikami S, et al. Patterns of interstitial lung
disease during everolimus treatment in patients with metastatic reï¿¾nal cell carcinoma. Jpn J Clin Oncol 42: 442-446, 2012.
18. Depuydt P, Nollet J, Benoit D, et al. Fatal acute pulmonary injury
associated with everolimus. Ann Pharmacother 46: e7, 2012.
19. Camus P. Interstitial Lung Disease from Drugs, Biologics, and Raï¿¾diation. In: Interstitial Lung Disease, 5th ed. Schwalz MI, King
TE Jr, Eds. Peopleâ€™s Medical Publishing House-USA, Shelton,
2010: 637-688.
20. Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of inï¿¾terstitial pneumonitis activity. Sialylated carbohydrate antigen KLï¿¾6. Chest 96: 68-73, 1989.
21. Ohnishi H, Yokoyama A, Yasuhara Y, et al. Circulating KL-6 levï¿¾els in patients with drug induced pneumonitis. Thorax 58: 872-
875, 2003.
â’¸ 2013 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imonline/index.html

